a.) Amendment to the Claims

1. (Currently Amended) ~~A Hsp90 family protein inhibitor comprising, as an active ingredient,~~ A method of inhibiting a Hsp90 family protein, comprising administering to a patient in need thereof, an effective amount of a benzoyl compound represented by general formula (I):



(I)

[wherein

n represents an integer of 0 to 10;

R^1 represents a hydrogen atom, hydroxy, cyano, carboxy, nitro, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyloxy, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylsulfonyl, a substituted or unsubstituted heterocyclic group, $CONR^7R^8$ (wherein R^7 and R^8 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aroyl, or R^7 and R^8 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or NR^9R^{10} (wherein R^9 and R^{10} have the same meanings as the above R^7 and R^8, respectively);

R^2 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group;

R^3 and R^5 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aroyl; and

R^4 and R^6 independently represent a hydrogen atom, hydroxy, halogen, cyano, nitro, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, amino, lower alkylamino, di-lower alkylamino, carboxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl], or

a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

2. (Currently Amended) ~~An Hsp90 family protein inhibitor comprising, as an active ingredient,~~ A method of inhibiting a Hsp90 family protein, comprising administering to a patient in need thereof, an effective amount of a benzoyl compound represented by general formula (I):



(I)

[wherein

n represents an integer of 0 to 10;

R^1 represents a hydrogen atom, hydroxy, cyano, carboxy, nitro, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyloxy, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylsulfonyl, a substituted or unsubstituted heterocyclic group, $CONR^7R^8$ (wherein R^7 and R^8

independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aroyl, or R^7 and R^8 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or NR^9R^{10} (wherein R^9 and R^{10} have the same meanings as the above R^7 and R^8, respectively);

R^2 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group;

R^3 and R^5 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aroyl; and

R^4 and R^6 independently represent a hydrogen atom, hydroxy, halogen, cyano, nitro, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, amino, lower alkylamino, di-lower alkylamino, carboxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryloxy, substituted or

unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl],

or a pharmaceutically acceptable salt thereof.

3. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 2, wherein R^1 is a hydrogen atom, hydroxy, cyano, carboxy, nitro, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyloxy, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylsulfonyl, $CONR^7R^8$ or NR^9R^{10}.

4. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 2, wherein R^1 is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, $CONR^7R^8$ or NR^9R^{10}.

5. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 2, wherein R^1 is $CONR^7R^8$.

6. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to any one of claims 2 to 5, wherein R^2 is substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group.

7. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 6, wherein R^4 is a hydrogen atom, hydroxy or halogen.

8. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 7, wherein R^3 and R^5, which may be the same or different, each are a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkanoyl, or substituted or unsubstituted aroyl.

9. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 6, wherein R^3, R^4 and R^5 each are a hydrogen atom.

10. (Currently Amended) ~~The Hsp90 family protein inhibitor~~ The method according to claim 9, wherein R^6 is a hydrogen atom, lower alkyl, halogen or aryl.

11. (Previously Presented) A benzoyl compound represented by general formula (IA):



(IA)

[wherein

nA represents an integer of 1 to 5;

R^{1A} represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, $CONR^7R^8$ (wherein R^7 and R^8 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aroyl, or R^7 and R^8 form a substituted or unsubstituted heterocyclic group together with the adjacent

nitrogen atom) or NR^9R^{10} (wherein R^9 and R^{10} have the same meanings as the above R^7 and R^8, respectively);

R^{2A} represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group;

R^{3A} and R^{5A} independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aroyl;

R^{4A} represents a hydrogen atom, hydroxy or halogen; and

R^{6A} represents a hydrogen atom, halogen, cyano, nitro, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, amino, lower alkylamino, di-lower alkylamino, carboxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl; provided that:

(i) when R^{3A} and R^{5A} each are methyl, R^{4A} and R^{6A} each are a hydrogen atom, and

$-(CH_2)_{nA}R^{1A}$ is

(a) methoxycarbonylmethyl,

R^{2A} is not a group selected from the group consisting of 2,4,6-trimethoxy-5-methoxycarbonyl-3-nitrophenyl, 3-cyano-2,4,6-trimethoxyphenyl, 5-cyano-2-ethoxy-4,6-dimethoxy-3-nitrophenyl, 2,6-dimethoxyphenyl, 2-chloro-6-methoxyphenyl and 2-chloro-4,6-dimethoxy-5-methoxycarbonyl-3-nitrophenyl,

(b) ethoxycarbonylmethyl;

R^{2A} is not 2,4,6-trimethoxy-3-methoxycarbonyl-phenyl, and

(c) N,N-dimethylaminomethyl,

R^{2A} is not phenyl;

(ii) when R^{3A}, R^{4A}, R^{5A} and R^{6A} each are a hydrogen atom, and -$(CH_2)_{nA}R^{1A}$ is

(a) 2-(acetoxymethyl)heptyl, 3-oxopentyl or pentyl,

R^{2A} is not 6-hydroxy-4-methoxy-3-methoxycarbonyl-2-pentylphenyl,

(b) 3-oxopentyl,

R^{2A} is not a group selected from the group consisting of 3-benzyloxycarbonyl-6-hydroxy-4-methoxy-2-pentylphenyl and 3-carboxy-6-hydroxy-4-methoxy-2-pentylphenyl, and

(c) n-propyl,

R^{2A} is not 2,4-dihydroxy-6-[(4-hydroxy-2-oxopyran-6-yl)methyl]phenyl;

(iii) when R^{3A} and R^{4A} each are a hydrogen atom, R^{5A} is methyl, R^{6A} is methoxycarbonyl, and $-(CH_2)_{nA}R^{1A}$ is pentyl;

R^{2A} is not a group selected from the group consisting of 6-[2-(acetoxymethyl)heptyl]-2,4-dihydroxyphenyl, 2,4-dihydroxy-6-pentylphenyl and 2,4-dihydroxy-6-(3-oxopentyl)phenyl;

(iv) when R^{3A} and R^{5A} each are benzyl, R^{4A} and R^{6A} each are a hydrogen atom, and $-(CH_2)_{nA}R^{1A}$ is 3-oxopentyl,

R^{2A} is not a group selected from the group consisting of 6-benzyloxy-4-methoxy-3-methoxycarbonyl-2-pentylphenyl and 6-benzyloxy-3-benzyloxycarbonyl-4-methoxy-2-pentylphenyl;

(v) when R^{3A} is benzyl, R^{4A} is a hydrogen atom, R^{5A} is methyl, $-(CH_2)_{nA}R^{1A}$ is pentyl, and R^{6A} is methoxycarbonyl or benzyloxycarbonyl,

R^{2A} is not 2,4-bis(benzyloxy)-6-(3-oxopentyl)-phenyl;

(vi) when R^{3A} and R^{4A} each are a hydrogen atom, R^{5A} is methyl, $-(CH_2)_{nA}R^{1A}$ is pentyl, and R^{6A} is carboxy or benzyloxycarbonyl,

R^{2A} is not 2,4-dihydroxy-6-(3-oxopentyl)phenyl; and

(vii) when R^{3A}, R^{4A} and R^{6A} each are a hydrogen atom, R^{5A} is n-propyl, and $-(CH_2)_{nA}R^{1A}$ is 5-(1,1-dimethylpropyl)-4-(2-hydrobenzotriazol-2-yl)-2-hydroxyphenylmethyl,

R^{2A} is not phenyl],

or a pharmaceutically acceptable salt thereof.

12. (Original) The benzoyl compound according to claim 11, wherein R^{2A} is a substituted or unsubstituted aromatic heterocyclic group, substituted aryl having 1 to 3 substituents, or aryl, or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The benzoyl compound according to claim 12, wherein R^{3A} and R^{5A} are independently a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, or substituted or unsubstituted lower alkenyl, or a pharmaceutically acceptable salt thereof.

14. (Previously Presented) The benzoyl compound according to claim 12, wherein R^{3A}, R^{4A} and R^{5A} each are a hydrogen atom, or a pharmaceutically acceptable salt thereof.

15. (Previously Presented) The benzoyl compound according to any one of claims 11 to 14, wherein R^{1A} is $CONR^{7}R^{8}$, or a pharmaceutically acceptable salt thereof.

16. (Previously Presented) The benzoyl compound according to any one of claims 11 to 14, wherein R^{6A} is a hydrogen atom, lower alkyl, halogen or aryl, or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the benzoyl compound according to claim 16 or a pharmaceutically acceptable salt of said benzoyl compound, together with a pharmaceutically acceptable carrier.

18. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, a prodrug of the benzoyl compound according to claim 16 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

19. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the benzoyl compound according to any one of claims 11 to 14, or

a pharmaceutically acceptable salt of said benzoyl compound, together with a pharmaceutically acceptable carrier.

20. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, a prodrug of the benzoyl compound according to any one of claims 11 to 14 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

Claims 21-25 (Cancelled).

26. (Previously Presented) A method of treating a disease associated with an Hsp90 family protein or a Hsp90 client protein, which comprises administering an effective amount of the benzoyl compound according to any one of claims 11 to 14 or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

27. (Previously Presented) A method of treating malignant tumors, which comprises administering an effective amount of the benzoyl compound according to any one of claims 11 to 14 or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Claims 28-31 (Cancelled).